EP3750528A1 - Zusammensetzungen zur behandlung von dystrophien und myotonie - Google Patents

Zusammensetzungen zur behandlung von dystrophien und myotonie Download PDF

Info

Publication number
EP3750528A1
EP3750528A1 EP19179559.0A EP19179559A EP3750528A1 EP 3750528 A1 EP3750528 A1 EP 3750528A1 EP 19179559 A EP19179559 A EP 19179559A EP 3750528 A1 EP3750528 A1 EP 3750528A1
Authority
EP
European Patent Office
Prior art keywords
thc
cbd
myotonia
combination according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19179559.0A
Other languages
English (en)
French (fr)
Inventor
Linda KLUMPERS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexien Biopharma Inc
Original Assignee
Nexien Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexien Biopharma Inc filed Critical Nexien Biopharma Inc
Priority to EP19179559.0A priority Critical patent/EP3750528A1/de
Publication of EP3750528A1 publication Critical patent/EP3750528A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Definitions

  • the present invention relates to the treatment of myotonia and dystrophies such as muscular dystrophies.
  • Myotonia is a condition present in a number of neuromuscular disorders such as myotonia congenital, paramyotonia congenital and myotonic dystrophy, and is characterized by a delayed relaxation of muscles after voluntary contraction.
  • Muscular dystrophy is a general term that describes a group of genetic muscular diseases wherein muscles weaken and breakdown over time without involvement of the nervous system. Some of the more common types of muscular dystrophy include:
  • dystrophies such as Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Emery-Dreifus Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, Limb-Girdle Muscular Dystrophy, Myotonic Muscular Dystrophy, or Oculopharyngeal Muscular Dystrophy.
  • myotonic dystrophy type 1 DM1
  • myotonic dystrophy type 2 DM2
  • the present invention provides, in one aspect, a combination comprising: a therapeutically effective amount of cannabidiol (CBD) or pharmaceutically effective salt, isomer or enantiomer thereof; a therapeutically effective amount of tetrahydrocannabinol (THC) or pharmaceutically effective salt, isomer or enantiomer thereof; and one or more pharmaceutically-acceptable excipients; for use in the treatment of the symptoms of myotonia in a subject in need thereof.
  • CBD cannabidiol
  • THC tetrahydrocannabinol
  • the myotonia is dystrophic (such as myotonic dystrophy type 1 (DM1) or myotonic dystrophy type 2 (DM2)); in other embodiments, the myotonia may be non-dystrophic myotonia.
  • DM1 myotonic dystrophy type 1
  • DM2 myotonic dystrophy type 2
  • the myotonia may be non-dystrophic myotonia.
  • the symptoms to be treated may include disabling grip; in cases of DM2, the symptoms to be treated may include painful stiffness in the subject's legs and neck.
  • the ratio by weight of CBD to THC may be in the range of about 1:1 to about 1:10; in some embodiments, the ratio is in the range of about 1:1 to about 6:1 or in the range of about 3:1 to about 6:1. In a particular embodiment, the ratio is 6:1.
  • a ratio of around 6:1 may be of utility, for example, in subjects resistant to other therapies, such as mexiletine treatment, lamotrigine treatment, tolperisone treatment, carbamazepine treatment, pregabalin treatment, flecainid treatment, and combinations thereof. Such subjects may, for example, have CLCN-1 congenital myotonia. Administration may, for example, be twice daily.
  • the administration may be topical, oral, nasal, inhalation or a combination thereof.
  • the combination may be applied to a patient's skin in the form of a patch, gel, cream, paste, lotion, ointment, salve, serum, spray, aerosol, mousse or foam.
  • the combination may be provided in a solid or liquid form that may be swallowed or held in the oral cavity.
  • the solid oral form may be a tablet, capsule, powder, or sachet, and may be administered in the solid form or dispersed or mixed with a food such as applesauce or oatmeal, or water, for easier swallowing.
  • the liquid oral form may be a solution, suspension or syrup that may be swallowed or applied to the oral cavity as a spray, mist, aerosol or drops.
  • the combination is administered nasally, it may be in form of a spray, mist or powder that is applied to the nasal cavity.
  • the composition may be delivered to a patient's respiratory system via a nebulizer, vaporization or a metered dose inhaler.
  • THC and CBD may, for example, be naturally occurring.
  • THC, CBD, or both cannabinoids may be synthetic.
  • the invention also extends to various salts, isomers and enantiomers thereof.
  • myotonia refers to any disorder or condition characterized by tonic spasm or temporary rigidity of a muscle and in particular the decreased relaxation of a muscle following a sustained contraction.
  • disorders that exhibit myotonia include myotonic dystrophy, myotonia congenital, and paramyotonia congenital.
  • the term "dystrophy” refers to any disorder or condition, particularly genetic conditions, characterized by degeneration in tissues, such as muscular tissue.
  • muscular dystrophies include Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Emery-Dreifus Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, Limb-Girdle Muscular Dystrophy, Myotonic Muscular Dystrophy, and Oculopharyngeal Muscular Dystrophy.
  • treat refers to providing relief of one or more of the symptoms associated with a particular condition or diminishing or lessening any one or more of the symptoms associated with the condition.
  • transdermal means delivery of a drug or biologically active substance by passage into and through the skin or mucosal tissue.
  • transdermal and “transmucosal” are used interchangeably unless specifically stated otherwise.
  • skin and “skin,” “derma,” “epidermis,” “mucosa” and the like will also be used interchangeably unless specifically stated otherwise.
  • topical refers to outer skin or derma of a patient.
  • phrase “topical application” refers to the application of a combination of the present invention and its various embodiments to the outer surface of a patient's skin or derma.
  • occlude refers to a transdermal formulation that is applied to the skin with the use of a supporting or otherwise associated structure.
  • a topical formulation may be applied to the skin of a patient with the aid of a structure, such as a backing member, bandage or cover.
  • a matrix patch is an example of an occluded device.
  • “unoccluded” and “non-occluded,” which may be used interchangeably, refer to a transdermal formulation that is applied to the skin without the use of a support, backing member, cover or otherwise associated structure.
  • the transdermal formulation is applied to the skin in a free form, which is sufficient to effect transdermal delivery of the drug or biologically active substance without the use of structures, such as a backing member, etc.
  • a gel formulation is an example of a non-occluded combination; other non-occluded combinations include ointments, lotions, pastes, mousses, aerosols and creams.
  • cannabinoid refers to any chemical known to activate cannabinoid receptors in cells.
  • the cannabinoids may be synthetic or naturally occurring. Naturally occurring cannabinoids may be found in cannabis plants or produced endogenously in humans and other animals. If produced endogenously, the cannabinoids are sometimes referred to as endocannabinoids. Synthetic cannabinoids are chemicals with similar structures to plant cannabinoids or endocannabinoids. Naturally occurring cannabinoids may be extracted and purified from various plants such as the cannabis plant, using known methods such as those described in U.S. Patent Nos. 7,344,736 ; 8,895,078 and 9,034,395 .
  • Synthetic cannabinoids are commercially available and can be prepared by known methods such as those described in U.S. Patent Nos. 3,668,224 ; 3,560,528 ; 7,186,850 ; 7,524,881 ; 7,674,922 ; 8,324,408 and 8,530,670 .
  • the invention relates particularly to the cannabinoids THC and CBD, which have the formulae shown below.
  • cannabinoids may also be present as pharmaceutically acceptable salts or as individual isomers, enantiomers or mixtures thereof.
  • the combinations of the present invention make possible methods for treating mammals, such as humans, that exhibit myotonia, such as myotonic dystrophy.
  • the methods of treating myotonia and/or dystrophies comprise the step of administering an effective amount of combination according to the invention to a patient in need of such treatment.
  • the term "effective amount" means the amount of an active substance, that, when administered to a subject for treating a disease, disorder, or other undesirable medical condition such as a myotonia or a dystrophy, is sufficient to have a beneficial effect with respect to that disease, disorder, or condition.
  • the therapeutically effective amount will vary depending on the chemical identity and formulation form of the active substance, the disease or condition and its severity, and the age, weight, and other relevant characteristics of the patient to be treated. Determining the therapeutically effective amount of a given active substance is within the ordinary skill of the art.
  • a beneficial effect can include, but is not limited to, reducing the period of time a patient experiences a myotonic event.
  • an effective amount of a combination according to the invention will reduce the decreased muscle relaxation or sustained muscle contraction time by at least about 5%, about 10%, about 15%, about 20%, about 25% about 30% or more. Accordingly, a patient being treated using a combination according to the present invention would exhibit normal muscle relaxation or muscle contraction time, or a reduced muscle relaxation or muscle contraction time lasting 1 minute or less, 30 seconds or less, 15 seconds or less, 10 seconds or less or 5 seconds or less.
  • Another beneficial effect can include a reduction in the pain a patient with myotonia and/or a dystrophy experiences.
  • the effect on pain can typically be measured using a visual analog scale (VAS) wherein the patient uses either a continuous horizontal or visual scale to indicate the pain he is experiencing.
  • VAS visual analog scale
  • the scale is based on 0-10 or 0-100 wherein "0" indicates no pain and "10" or "100” indicates that pain is agonizing, unbearable or "worst imaginable.”
  • VAS visual analog scale
  • the patient will indicate the pain level using a VAS prior to treatment and after an effective amount of a combination according to the invention has been administered. It is believed that the administration of an effective amount of a combination according to the invention will reduce pain by at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30% or more.
  • a further beneficial effect can include an improvement or delayed reduction in muscle weakness as determined by the Motor Function Measure (MFM).
  • MFM is a generic scale which provides a measurement of the effects of muscle weakness in neuromuscular weakness in neuromuscular diseases.
  • the MFM-32 test includes 32 assessments for patients 6 to 60 years of age and the MFM-20 test includes 20 assessments for patients under 7 years of age. More details on the MFM tests and assessments can be found at http://www.motor-function-measure.org and Berard et al., "A Motor Function Measure Scale for Neuromuscular Diseases. Construction and Validation Study," Neuromuscular Disorders 15 (2005) pp. 463-470 .
  • the patient may be evaluated using the MFM prior to treatment and after an effective amount of the combination according to the invention has been administered. It is believed that the administration of a combination according to the invention will improve the MFM score by at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30% or more and/or delay the time of the expected deterioration as measured by the MFM score by at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30% or more.
  • the administration of the effective amount of a combination according to the invention may occur about every 2 to about 3 hours, about every 4 to about 6 hours, about every 6 to about 8 hours about every 12 hours, or about every 24 hours. In certain instances the administration may occur once, twice three or four times a day. In some cases, the administration of the combination occurs about every 4 to 8 hours or every 8 to 12 hours.
  • the combination may be administered concurrently, such as in the same dosage form, i.e., both CBD and THC being present in the same tablet, capsule, liquid, suspension aerosol, or topical patch, gel, cream lotion or serum.
  • the combined administration may alternatively occur sequentially, wherein either the CBD or the THC is administered at a first time and the other is administered at a second time, and the first and second times are different.
  • the first and second times may be separated by a few seconds such as 30 seconds, a few minutes such as about 1 to 20 minutes preferably 1 to 10 minutes and most preferably about 1 to about 5 minutes or by an hour or more.
  • the effective amount of the CBD and THC will vary depending upon the route of administration, and the patient's individual characteristics such as age weight, sex, it is believed that the effective amount each of the CBD and THC will range from about 0.01 mg to about 1000 mg per administration, preferably about 0.05 mg to about 800 mg per administration, and most preferably about 0.1 mg to about 700 mg per administration. It is further believed that the forgoing dosing ranges are based on the total amount of cannabinoid being administered per dose. For example, the total amount of cannabinoid, i.e., THC and CBD being administered should be within the aforementioned ranges.
  • CBD One effect of the CBD is to counteract the psychotropic or "high" effects of THC.
  • the administration of the effective amount of the combination according to the invention may be by any means commonly known in the art such as topical, nasal, oral, inhalation or a combination thereof.
  • a method for treating myotonia or a dystrophy comprises the administration of 1 mg to 1000 mg, preferably 2.5 mg to 850 mg, and most preferably 3 mg to 700 mg, of a combination according to the invention.
  • a method for treating myotonia or a dystrophy comprises the administration of 1 mg to 1000 mg, preferably 2.5 mg to 850 mg, and most preferably 3 mg to 700 mg, of a combination according to the invention.
  • the ratio of CBD to THC may range from 1:1 to 1:200, preferably 1:1.5 to 1:190 and most preferably 1:1 to 1:180.
  • a method for treating myotonia or a dystrophy comprises the administration of 0.01 mg to 1000 mg, preferably 0.05 mg to 850 mg, and most preferably 0.1 mg to 700 mg, of a combination according to the invention.
  • the ratio of CBD to THC may range from 1:1 to 1:200, preferably 1:1.5 to 1:190 and most preferably, 1:1 to 1:180.
  • the method for treating myotonia or a dystrophy comprises the administration of 0.01 mg to 1000 mg, preferably 0.05 mg to 850 mg, and most preferably 0.1 mg to 700 mg, of a combination according to the invention; wherein the ratio of CBD to THC may range from 1:1 to 1:200, preferably 1:1.5 to 1:190 and most preferably 1:1 to 1:180.
  • the methods of treatment made possible by the present invention comprise the administration, preferably the oral administration, of a tablet, capsule or liquid (i.e., solution or suspension) comprising a combination of THC and CBD in a ratio of about 1:1 to 1:200, preferably 1:1.5 to 1:190 and most preferably 1:1 to 1:180.
  • the oral administration will occur once, twice, three or four times a day, preferably two or three times a day.
  • Each administration will comprise: (i) about 1-100 mg of THC, preferably 2-75 mg of THC and most preferably 5-50 mg of THC and (ii) about 1-1000 mg of CBD, preferably 2-850 mg of CBD and most preferably 5-700 mg of CBD.
  • the target of the oral administration is to obtain a steady state plasma level of THC ranging from 0.25 ng/mL to 25 ng/mL, preferably 0.5 ng/mL to 17.5 ng/mL and most preferably 1 ng/mL to 12.5 ng/mL, and a steady state plasma level of CBD greater than 0.5 ng/mL, preferably greater than 1 ng/mL and most preferably greater than 3 ng/mL.
  • the foregoing administrations and target pharmacokinetic steady state plasma levels will be effective in the treatment of myotonia or a dystrophy, preferably myotonic dystrophy.
  • the foregoing administrations will reduce the pain associated with the myotonia or dystrophy, improve the muscle movement and provide an overall improvement in the quality of a patient's life.
  • the administration will enable a quicker relaxation of a patient's muscles following contraction than without administration and thereby should improve muscle movement and improve the patient's quality of life.
  • the present invention includes pharmaceutical compositions that are useful in the treatment of myotonia and/or dystrophies.
  • the pharmaceutical compositions in accordance with the present invention include: a therapeutically effective amount of cannabidiol (CBD) or a pharmaceutically effective salt, isomer or enantiomer thereof; a therapeutically effective amount of tetrahydrocannabinol (THC) or a pharmaceutically effective salt, isomer or enantiomer thereof; and one or more pharmaceutically-acceptable excipients.
  • CBD cannabidiol
  • THC tetrahydrocannabinol
  • the pharmaceutically acceptable carrier(s) or excipient(s) are known in the art and their selection will depend upon the route of administration.
  • the topical compositions include occluded forms, such as matrix and reservoir patches, and unoccluded forms, such as gels, creams, lotions, ointments, and serums, as wells as topical foams and mousses.
  • a matrix patch in accordance with the present invention comprises a combination according to the invention, homogeneously blended in a solid or semisolid polymer carrier together with other additives (e.g., permeation enhancers, plasticizers, viscosity reducing agent, and the like).
  • additives e.g., permeation enhancers, plasticizers, viscosity reducing agent, and the like.
  • the matrix patch comprises an occlusive backing that is impermeable to the CBD and THC and defines the face or top surface of the patch and a solid or semisolid matrix layer comprised of a combination according to the invention and one or more skin permeation enhancers.
  • the polymeric carrier may be adhesive or nonadhesive. When it is a pressure sensitive adhesive the basal surface of the matrix layer may be used to affix the patch to the skin. When it is not, other means such as an underlying adhesive layer, a peripheral adhesive layer, an adhesive overlay, or straps may be used to affix the patch to the skin.
  • polyacrylates examples, without limitation, of specific polymers that may be used as the carrier are polyacrylates, polymethacrylates, natural and synthetic rubbers, silicone rubbers and elastomers, polyolefins, vinyl copolymers, urethanes, nylons, polyesters, polyethers, and the like.
  • the skin permeation enhancer(s) that are included in the matrix enhance the level of skin flux of CBD and THC.
  • permeation enhancers that may be used in compositions of the present invention include, but are not limited to, fatty acids, fatty acid esters, fatty alcohols, fatty acid esters of lactic acid or glycolic acid, glycerol tri-, di- and monoesters, triacetin, short chain alcohols, amine oxides and mixtures thereof.
  • permeation enhancers include oleyl alcohol, lauryl alcohol, isopropyl myristate, oleyl oleate, levulinic acid, ethanol, glycerol monooleate, methyl laurate, sorbitain monooleate, triacetin, aloe vera oil, benzothonium chloride, cetyl dimethylamine oxide, cetyl alcohol, cetyl lactate, cocamidopropyl betaine, cocoamine oxide diethanolamine, dimethyloctylamine oxide, 2-dodecoxyethyldimethylamine oxide, dimethyl-decylamine oxide, dimethylhexadecylamine oxide, dimethyl-tetradecylamine oxide, dimethyl isosorbide, dipropylene glycol, ethyl hexyl lactate, glycolic acid, 3-dodecoxy-2-hydroxypropyldi(3-hydroxypropyl)amine oxide, lactic acid, lauramine oxide
  • permeation enhancers useful with the present invention may be found in U.S. Patent Application Publication No. 2007/0269379 .
  • Preferred permeation enhancers include oleyl alcohol, lauryl alcohol, isopropyl myristate, oleyl oleate, levulinic acid, glycerol monooleate, methyl laurate, sorbitain monooleate, triacetin, cetyl alcohol, cetyl lactate, dimethyl isosorbide, dipropylene glycol, ethyl hexyl lactate, glycolic acid, lauramine oxide, lauryl betaine, lauryl lactate, lauryl laurate, isopropyl palmitate, myristyl alcohol, myristal lactate, octyl salicylate, oleamine oxide, oleic acid, oleyl betaine, salicylic acid, stearyl alcohol, stearyl lactate, triethanolamine triacetate and combinations
  • the patches of the invention may be manufactured by conventional techniques used in transdermal drug delivery device art.
  • the CBD, THC, carrier, and enhancer(s) may be mixed in the desired proportions to form a homogeneous mixture and cast or otherwise applied to a backing layer, by lamination to a release liner layer.
  • Reservoir patches in accordance with the present invention may comprise a gelled liquid solution or suspension containing CBD, THC and an enhancer within a carrier or be in the form of a fibrous body impregnated with the drug in the carrier.
  • the device includes means for maintaining the reservoir in diffusional communication with the skin.
  • Such means include a carrier which is also an adhesive, a separate basal adhesive layer underlying the reservoir, a peripheral ring of adhesive that is interconnected to the reservoir, an adhesive overlay for the reservoir, and straps.
  • the means is either an adhesive carrier or a separate underlying adhesive layer.
  • the patches may further include a backing that overlies the reservoir and protects the reservoir and/or prevents back-diffusion of the CBD, THC and enhancer from the reservoir, one or more structural layers to provide the device with appropriate mechanical properties, and/or a release liner layer that underlies the reservoir and which is removed prior to use and means for affixing the device to the skin.
  • the carrier or vehicle is permeable to the CBD, THC and the permeation enhancer.
  • the carrier is a fluid (e.g., liquid, gel, emulsion, suspension). It may be aqueous or nonaqueous.
  • fluid carriers that may be used are alcohols such as ethanol, alcohol-water mixtures, and low molecular weight polymers such as polyethylene glycol. Ethanol is preferred and also provides permeation enhancement.
  • the carrier normally constitutes 20% to 70% by volume of the reservoir, more usually 40% to 60%, and preferably approximately 50%.
  • the carrier may be a solid or semisolid matrix such as a pressure-sensitive adhesive.
  • the reservoir patches may contain a permeation enhancer as discussed above.
  • the reservoir may also contain amounts of other materials such as gelling agents and anti-irritants.
  • Glycerin is a preferred anti-irritant and may be present at 5% to 50%, preferably 20% to 30% by volume. The use of glycerin as an anti-irritant is described in U.S. Pat. No. 4,855,294 .
  • the reservoir patches may be manufactured by conventional techniques used in the transdermal drug delivery device art. For instance, CBD, THC, a permeation enhancer and carrier may be mixed in the desired proportions to form a homogeneous mixture and cast or otherwise applied to a backing layer, followed by lamination to a release liner layer. If a separate basal adhesive layer is desired, it may be cast onto the release liner layer prior to such lamination.
  • the patches will be typically designed to be worn for 0.5 to 14 days, more preferably 1 to 7 days, and most preferably 1-3 days.
  • the thickness of the matrix layer may be 0.01 to 1 mm, more preferably 0.025 to 0.25 mm.
  • the thickness of the reservoir will usually be about 0.01 to 5 mm, more usually 0.03 to 2 mm.
  • the area of the patch in diffusional contact with the skin may be between 1 and 150 cm 2 , more preferably 5 and 100 cm 2 , and most preferably 10 and 75 cm 2 .
  • the required dosing may be supplied by a single device or by a plurality of devices applied to the skin.
  • a further embodiment of the present invention is directed to topical gels, creams, lotions, ointments, serums, foams, and mousses of a combination according to the invention (collectively “unoccluded topical dosage forms").
  • the unoccluded topical dosage forms may contain a penetration enhancer as discussed above.
  • the topical dosage form may also include further additives such as solvents, film forming/polymeric agents, viscosity increasing agents, emulsifiers, antioxidants, preservatives, pH adjusting agents, propellants and combinations of the foregoing.
  • the unoccluded topical dosage forms may be uniform compositions, emulsions, such as oil-in-water or water-in-oil emlusions, or liposomal compositions.
  • the unoccluded topical dosage forms of the present invention may include any suitable solvent.
  • the solvent may include water and/or one or more organic compounds, e.g., esters, alcohols, ketones, aldehydes, fatty acids, partially or fully esterified fatty acids, wherein the structures are cyclic, non-cyclic (e.g., alkyl), alicyclic (i.e., a bridged ring compound), or aromatic, as well as organic compounds having combinations of these functional groups.
  • solvents that may be employed are water, methanol, ethanol, isopropyl alcohol, acetone, hexane, butyl alcohol, ethyl acetate, polyethylene glycol, propylene glycol, ethylene glycol, triethylene glycol, glycerin, 1,3-propane diol, 2-methyl-1,3-propane diol, glycerol ricinoleate, mineral oil, peanut oil, corn oil, cottonseed oil, sesame oil or a combination thereof.
  • the solvent may be employed in any suitable amount.
  • the solvent can be present in the unoccluded topical composition in about 1.0 wt % to about 95.0 wt % based upon the total weight of the unoccluded topical dosage form, preferably about 3.0 wt % to about 85 wt % based upon the total weight of the unoccluded topical composition and most preferably about 5.0 wt % to about 75 wt % of the total weight of the unoccluded topical composition.
  • the unoccluded topical dosage forms of the present invention also may optionally include a film-forming/polymeric agent.
  • the film-forming/polymeric agent may enhance the adherence of the composition to the patient's skin and improve the composition's resistance to washing off or rubbing off.
  • Film-forming/polymeric agents are preferably soluble or miscible with the CBD, THC, solvent and/or penetration enhancer.
  • the unoccluded topical dosage forms of the present invention typically comprises from about 0.001 wt % to about 25 wt %, preferably about 0.005 wt % to about 15 wt % and most preferably about 0.010 wt % to about 10 wt % based upon the total weight of the unoccluded topical composition of the film-forming/polymeric agents.
  • film-forming/polymeric agents that may be used in compositions of the present invention are polyalkenes, oleophilic copolymers of vinvylpyrrolidone, acrylic copolymers, polyethylene glycol derivative, polyolefins, polyurethanes and mixtures thereof.
  • polyalkenes examples include polyethylenes having a molecular weight ranging from about 300 to about 3000 (available as PERFORMALENE® from New Phase Technologies, Piscataway, N.J.); polyisobutylenes (available as VISTANEXTM from Exxon Chemical Company, Houston, Tex.); polyisobutenes (available as PRESPERSETM from Sumitomo Corp.); polydecenes (SILKFLOTM available from Amoco); and hydrogenated polyisobutenes (PANALANE® available from Lipo Chemicals, Inc., Paterson, N.J.).
  • polyethylenes having a molecular weight ranging from about 300 to about 3000 available as PERFORMALENE® from New Phase Technologies, Piscataway, N.J.
  • polyisobutylenes available as VISTANEXTM from Exxon Chemical Company, Houston, Tex.
  • polyisobutenes available as PRESPERSETM from Sumitomo Corp.
  • Oleophilic copolymers of vinylpyrollidone suitable for use in the topical dosage forms of the present invention may be copolymers of polyvinylpyrrolidone (PVP) and long chain alpha olefins, including, but not limited to, PVP/eicosene copolymers (GANEX® V-220 and V-220F), and tricontanyl PVP copolymers (GANEX®) available from Ashland, formerly International Specialty Products, Wayne, N.J.
  • PVP polyvinylpyrrolidone
  • GNEX® V-220 and V-220F long chain alpha olefins
  • acrylic copolymers examples include acrylic copolymers having long (C 8 -C 30 ) alkyl chains to enhance their oleophilicity, such as acrylate/octylacrylamide copolymers (available as DERMACRYL® from Akzo Nobel).
  • An example of a polyethylene glycol derivative that may be used as a film forming agent in compositions of the present invention is a polyethylene glycol derivative of Beeswax (ESTOL® E04BW-3752, E06BW-3753 or E03BW-3751 formerly available from Unichema, Wilmington, Del. and currently available from Croda under the trade name CITHROL®).
  • the film forming/polymeric agents may water-insoluble, oleophilic, water-resistant, or water-soluble.
  • the unoccluded topical dosage forms of the present invention may also contain viscosity enhancing agents that thicken, gel or harden the composition.
  • An unoccluded topical dosage forms in accordance with the present invention such as a topical gel, typically comprises from about 0.001 wt % to about 50 wt % of the viscosity enhancing agent, preferably about 0.005 wt % to about 40 wt % and most preferably about 0.01 wt % to about 25 wt % based upon the total weight of the unoccluded topical composition.
  • Exemplary viscosity enhancing agents include organic materials such as natural or synthetic waxes, C 12 -C 60 alcohols, C 12 -C 60 acids, alpha-hydroxy fatty acids, polyhydroxy fatty acid esters, polyhydroxy fatty acid amides, and inorganic/organic materials such as metal ester complexes containing zinc, calcium, aluminum or magnesium, fumed silicas, and organoclays.
  • Additional viscosity enhancing agents include polyol polyesters, glyceryl esters, polyglyceryl esters and polysiloxanes that are a solid or semi-solid at ambient temperature.
  • Other suitable viscosity enhancing agents include C 12 -C 60 acids, preferably C 16 -C 22 fatty acids, such as palmitic acid, stearic acid, behenic acid, oleic acid, linoleic acid, myristic acid, ricinoleic acid, eurcic acid, lauric acid, isostearic acid and mixtures thereof.
  • suitable viscosity enhancing agents that may be used herein are alpha-hydroxy fatty acids, including 12-hydroxystearic acid, 12-hydroxylauric acid, 16-hydroxyhexadecanoic acid and mixtures thereof. Additional examples of suitable fatty acids are further described in Klofta et al., U.S. Pat. No. 7,449,613 , Hofrichter, et al., U.S. Pat. No. 5,429,816 and Motley, U.S. Pat. No. 5,552,136 .
  • Waxes are also suitable for use as viscosity enhancing agents in unoccluded topical dosage forms of the present invention.
  • Natural waxes may include, but are not limited to, carnauba, ozokerite, beeswax, candelilla, paraffin, ceresin, esparto, ouricuri, rezowax and other known mined and mineral waxes.
  • Synthetic waxes may include, but are not limited to, paraffin waxes and microcrystalline waxes.
  • Additional viscosity enhancing agents that may be used include polyhydroxy fatty acid esters, polyhydroxy fatty acid amides and mixtures thereof.
  • Preferred esters and amides will have three or more free hydroxy groups on the polyhydroxy moiety and are typically nonionic in character. Because of the possible skin sensitivity of those using articles to which the unoccluded topical dosage form is applied, these esters and amides should also be relatively mild and non-irritating to the skin.
  • Suitable polyhydroxy fatty acid esters and polyhydroxy fatty acid amides are disclosed in Roe et al., U.S. Pat. No. 5,643,588 .
  • Gelling agents are materials that can swell or expand when in contact with water.
  • examples of gelling agents that may be used in the present invention include swellable polymers, also known as osmopolymers or hydrogels as previously described.
  • the swellable polymer can be non-cross-linked or lightly cross-linked.
  • the cross-links can be covalent or ionic bonds with the polymer possessing the ability to swell in the presence of fluid, and when cross-linked it will not be dissolved in the fluid.
  • the polymer can be of plant, animal or synthetic origin.
  • Polymeric materials useful for the present purpose include polyhydroalkylcellulose having a molecular weight greater than 50,000, such as hydroxyl propylmethylcellulose (METHOCEL® K 100M available from Dow Chemical); poly(hydroxyalkylmethacrylate) having a molecular weight of from 5,000 to 5,000,000; poly(vinylpyrrolidone) having a molecular weight of from 100,000 to 3,000,000; anionic and cationic hydrogels; poly(electrolyte) complexes; poly(vinylalcohol) having a low acetate residual; a swellable mixture of agar and carboxymethyl cellulose; a swellable composition comprising methyl cellulose mixed with a sparingly cross-linked agar; a polyether having a molecular weight of from 10,000 to 6,000,000; a water-swellable copolymer produced by a dispersion of a finely divided copolymer of maleic anhydride with styrene, ethylene, propy
  • gelling agents useful in the unoccluded topical dosage forms of the present invention include pectin having a molecular weight ranging from 30,000 to 300,000; polysaccharides such as agar, acacia, karaya, tragacanth, algins and guar; CARBOPOL®, an acrylic acid polymer, a carboxyvinyl polymer, sometimes referred to as carboxypolymethylene, a polymer of acrylic acid cross-linked with a polyallyl ether of sucrose, as described in U.S. Pat. Nos.
  • CARBOPOL® 934, 940 and 941, and its salt derivatives polyacrylamides; water-swellable indene maleic anhydride polymers; GOOD-RITE® polyacrylic acid having a molecular weight of 80,000 to 200,000; POLYOX® polyethylene oxide polymers having a molecular weight of 100,000 to 7,000,000; starch graft copolymers; AQUA-KEEP® acrylate polymers with water absorbability of about 400 times its original weight; diesters of polyglucan; a mixture of cross-linked polyvinyl alcohol and poly(N-vinyl-2-pyrrolidone); poly(ethylene glycol) having a molecular weight of 4,000 to 100,000.
  • inorganic viscosity enhancing agents that may be included in the unoccluded topical dosage forms of the present invention include treated and untreated fumed silicas such as those available from Cabot Corp., Tuscola, Ill. under the trade designations CAB-O-SIL M5 and MS-55. Exemplary surface-treated fumed silicas are also available from Cabot Corp., Tuscola, Ill. under the trade designations TS-720 and TS-610.
  • Suitable clays such as hectorite and smectite may also be used as viscosity enhancing agents in unoccluded topical dosage forms of the present invention.
  • Hydrogenated vegetable oils such as cocoa butter, shea butter and mixtures thereof may also be used as viscosity enhancing agents in unoccluded topical dosage forms of the present invention.
  • Suitable petroleum-based emollients may also be used as viscosity enhancing agents in unoccluded topical dosage forms of the present invention.
  • suitable petroleum-based emollients that may be used include petrolatums, i.e., hydrocarbons or mixtures of hydrocarbons; particularly preferred are hydrocarbons having chain lengths of from C 10 to C 100 .
  • Petroleum-based emollients within this chain length range include mineral oil and petrolatum.
  • Mineral oil usually refers to less viscous mixtures of hydrocarbons having from 10 to 30 carbon atoms, though the hydrocarbon molecular weight distribution may vary. Since the lower molecular weight hydrocarbons can cause irritation in some individuals, mineral oils having a small percentage of lower molecular weight hydrocarbons are preferred.
  • Petrolatum usually refers to more viscous mixtures of hydrocarbons of higher molecular weight hydrocarbons.
  • Petrolatum and mineral oil are preferred skin conditioning agents for compositions of the present invention due to their ability to protect the skin from harmful or irritating stimuli.
  • Petrolatum is particularly preferred because of its good barrier properties.
  • the unoccluded topical dosage forms of the present invention may also contain humectants.
  • Unoccluded topical dosage forms in accordance with the present invention typically comprises from about 0.001 wt % to about 30 wt % of a humectant, preferably about 0.005 wt % to about 20 wt % and most preferably about 0.01 wt % to about 10 wt % based upon the total weight of the unoccluded topical composition.
  • Examples of compounds that may be used as humectants in compositions of the present invention are esters of polyhydroxy alcohols.
  • This type of ester may include glyceryl esters including glycerides and derivatized glycerides, polyglyceryl esters, and glycolic esters.
  • Glyceryl esters are derived from glycerin, its derivatives and one or more carboxylic acid moieties.
  • Non-limiting examples include various C 1 -C 30 mono-, di- or tri-esters of glycerin and derivatives thereof, such as mono-, di-, tri-glycerides, acetoglycerides, and ethoxylated glycerides.
  • Exemplary glyceryl esters include glyceryl behenate, glyceryl oleate, glyceryl stearate, glyceryl palmitate, glyceryl distearate, glyceryl dipalmitate and the like.
  • Polyglyceryl esters having C 12 -C 22 acid moieties are also suitable for use herein. Non-limiting examples include polyglyceryl-4 isostearate, polyglyceryl-3 oleate, diglyceryl monooleate, tetraglyceryl monooleate and the like.
  • Glycolic esters are derived from C 2 -C 6 glycols, including ethylene glycol, propylene glycol, butylene glycol, hexylene glycol and derivatives thereof, and one or more carboxylic acid moieties having C 1 -C 30 chains.
  • glycolic esters include polyethylene glycols (PEGs), such as PEG-2, PEG-3, PEG-30 and PEG-50, and polypropylene glycols (PPGs), such as PPG-9, PPG-12, PPG-15, PPG-17, PPG-20, PPG-26, PPG-30 and PPG-34.
  • the unoccluded topical dosage forms of the present invention may also contain emulsifiers or dispersing agents such as anionic, cationic and nonionic surfactants.
  • Unoccluded topical dosage forms in accordance with the present invention typically comprises from about 0.001 wt % to about 15 wt % of an emulsifier or dispersing agent, preferably about 0.005 wt % to about 10 wt % and most preferably about 0.01 wt % to about 5 wt % based upon the total weight of the unoccluded topical composition.
  • Nonionic surfactants are preferred because of their low level of irritation to skin.
  • Typical nonionic surfactants are monoglycerides such as glyceryl monostearate and the like; sorbitan aliphatic esters such as sorbitan monolaurate and the like; sucrose aliphatic esters; polyoxyethylene aliphatic esters such as polyoxyethylene stearate; and polyoxyethylene higher alcohol ethers such as polyoxyethylene cetyl ether, polyoxyethylene oleyl ether, polyoxyethylene fatty ethers and the like.
  • the unoccluded topical dosage forms of the present invention may also contain an antioxidant to minimize or prevent the oxidation process and enhance the shelf life of the composition.
  • Unoccluded topical dosage forms in accordance with the present invention typically comprises from about 0.001 wt % to about 25 wt % of an anti-oxidant, preferably about 0.005 wt % to about 15 wt % and most preferably about 0.01 wt % to about 10 wt % based upon the total weight of the unoccluded topical composition.
  • Antioxidants useful herein should preferably be mild and non-irritating.
  • Antioxidants from natural sources are preferred, such as Vitamin E and its derivatives, including tocopherol, tocopherol acetate, mixed tocopherols (available as COVI-OX T-50 or T-70 from Henkel Corp, Ambler, Pa.), and the like or butylated hydroxytoluene, butylated hydroxyanisole, sodium pyrosulfite, acetone sodium bisulfate and the like. Some of these antioxidants are also useful as skin antioxidants, which minimizes the wrinkles and dullness of the skin and provides a more youthful looking and firmer textured skin.
  • Vitamin E and its derivatives including tocopherol, tocopherol acetate, mixed tocopherols (available as COVI-OX T-50 or T-70 from Henkel Corp, Ambler, Pa.), and the like or butylated hydroxytoluene, butylated hydroxyanisole, sodium pyrosulfite, acetone sodium bisulfate and the like.
  • the unoccluded topical dosage forms of the present invention may also contain a preservative to prevent bacterial growth and odors thereof, particularly in compositions having a relatively high water content.
  • Unoccluded topical dosage forms in accordance with the present invention typically comprise from about 0.001 wt % to about 10 wt % of a preservative, preferably about 0.005 wt % to about 5 wt % and most preferably about 0.01 wt % to about 2.5 wt % based upon the total weight of the unoccluded topical composition.
  • Suitable preservatives include propyl paraben, methyl paraben, benzyl alcohol, benzalkonium chloride, tribasic calcium phosphate, phenoxyethanol, or acids such as citric, tartaric, maleic, lactic, malic, benzoic, salicylic, and the like.
  • the unoccluded topical dosage forms of the present invention may include an acid or base to adjust the pH of the composition to the desired or optimal range.
  • examples of compounds typically used to adjust the pH of topical compositions include oleic acid, hydrochloric acid, citric acid, lactic acid, tartaric acid, glacial acetic acid, sodium hydroxide or the like.
  • the desired final pH value of the composition may vary, however, it is generally preferred that the composition range from a pH of about 5.0 to about 8.5, preferably about 6 to about 8.0, and most preferably about 6.5 to about 7.5.
  • Suitable chelating agents may include ethylenediaminetetraacetic acid (EDTA) and its derivatives, thioglycolic acid, thiolactic acid, thioglycerol, and the like.
  • EDTA ethylenediaminetetraacetic acid
  • a fragrance may also be added to unoccluded topical dosage forms of the present invention if desired.
  • the composition will require a propellant for dispensing the composition from the container.
  • the propellant may be any type of propellant commonly used in the cosmetic/pharmaceutical industry such as nitrogen, carbon dioxide, dimethyl ether, hydrocarbons, i.e., methane, ethane, propane, butanes and pentanes, halogenated hydrocarbons, i.e., CH 2 ClF, CClF 2 CHClF, CF 3 CHClF, CHF 2 CClF 2 , CHClFCHF 2 , CF 3 CH 2 Cl, CClF 2 CH 3 , CHF 2 CHF 2 , CF 3 CH 2 F (HFC 134a), CHF 2 CH 3 (HFC 152a), CF 3 CHFCF 3 (HFC 227), CF 3 CF 3 and CF 3 CF 2 CF 3 .
  • hydrocarbon propellants are A-46 (15.2% propane/84.8% isobutene); and NP-46 (25.9% propane/74.1% n-butane), NIP-46 (21.9% propane/31.3% isobutene/46.8% n-butane).
  • the amount of propellant will depend on the type of container for the composition of the present invention, the amount of the composition in the container, the amount of composition to be dispensed per actuation and the form in which the composition will be dispensed, i.e., mist or foam.
  • the optimization of the propellant and container are within the ability of the skilled artisan and examples can be found in Wai-Chiu So et al., U.S. Pat. No.
  • the propellant is generally not included in the calculation of the weight percentages of the composition prepared in accordance with the present invention because it is merely part of the dispensing device and typically does not remain part of the composition once the composition is dispensed and applied to the patient's skin.
  • the aerosols, foams and mousses of the present invention will include a solvent, preferably water and/or a lower alcohol, i.e., C 1 -C 6 alcohols such as methanol, ethanol, isopropanol or mixtures thereof.
  • the aerosols, foams or mousses may also comprise a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, polyethylene glycol 400, hexylene glycol and dipropylene glycol or glycerol.
  • the co-solvent When the co-solvent is present, it may be present in amounts of approximately 10% by weight or less, preferably approximately 5% by weight or less based upon the total weight of the composition.
  • the emulsions of the present invention are either water-in-oil (W/O) emulsions or oil-in-water (O/W) emulsions, and may include, but are not limited to, cetyl alcohol, glyceryl monostearate, lanolin, polyalkylsiloxanes, and stearic acid.
  • Water-soluble ointment bases suitable for use in the present invention may be prepared from polyethylene glycols of varying molecular weight.
  • Emulsion formulations are generally formed from a dispersed phase (e.g., a pharmacologically active agent), a dispersion medium and an emulsifying agent. If desired, emulsion stabilizers can be included in the formulation as well.
  • Emulsifying agents suitable for use in such formulations include, but are not limited to, TWEEN 60®, Span 80®, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulfate.
  • W/O emulsions may be prepared by taking a mixture of the active agent(s) with oil phase ingredients, bacteriostats/preservatives and buffer salts which are dissolved or suspended therein and to which water has been added to form a water-in-oil emulsion.
  • O/W emulsions are semisolid emulsions, micro-emulsions, or foam emulsion systems containing the active agent(s). Usually such a system has a "creamy white" appearance.
  • the internal oil phase is in the range in percentage composition of about 10% to about 40% oil by weight and the external phase may contain 80% or more water.
  • the oleaginous phase may contain, but is not limited to, long-chain alcohols (cetyl, stearyl), long-chain esters (myristates, palmitates, stearates), long-chain acids (palmitic, stearic), vegetable and animal oils and assorted waxes. These can be made with anionic, cationic, nonionic or amphoteric surfactants, or with combinations especially of the nonionic surfactants.
  • the oral compositions include both solid and liquid dosage forms.
  • Solid dosage forms include but are not limited to tablets, capsules, pellets, granules, powders.
  • the liquid dosage forms include syrups, solutions and suspensions.
  • the oral compositions may be swallowed or applied to the oral cavity, i.e., sublingually, lingually or buccally.
  • the oral compositions may be formulated to be immediate release, controlled release, or a combination thereof.
  • the CBD and THC may be combined with pharmaceutically acceptable excipients such as fillers, diluents, binders, stabilizing agents, lubricants, disintegrants or mixtures thereof.
  • pharmaceutically acceptable excipients are well known in the art and are described in Remington, the Science and Practice of Pharmacy, 21st Ed. (2006), pp. 1058-1092, published by Lippincott Williams & Wilkins ; United States Pharmacopeia 27 (2004), pp. 2809-2812 ; and Handbook of Pharmaceutical Excipients, 5th Ed. (2006), published by the Pharmaceutical Press .
  • the solid oral dosage forms are made by methods commonly known in the art such as direct compression, wet or dry granulation, and extrusion spheronization.
  • the solid oral dosage form is a soft gel capsule wherein the CBD and THC are dissolved or suspended in a suitable solvent, such as mineral or vegetable oil and mixed with other conventional excipients to prepare the soft gel capsule.
  • acceptable fillers include water, sugars such as lactose, dextrose, sucrose, maltose, or microcrystalline cellulose, clays, and mixtures thereof.
  • Binders that are useful in the present invention include pharmaceutically acceptable substances with cohesive properties. Some examples include celluloses such as hydroxypropyl methycellulose, hydroxypropyl cellulose and carboxymethycellulose sodium, polyvinylpyrrolidone, sugars, starches, and mixtures thereof.
  • stabilizing agents examples include organic acids and alkaline metal salts of organic acids, such as succinic acid, fumaric acid, citric acid, sodium citrate, and mixtures thereof.
  • lubricants, glidants and/or antiadherents examples include talc, magnesium stearate, calcium stearate, stearic acid, hydrogenated vegetable oils, polyethylene glycols, silicon dioxide, and mixtures thereof.
  • disintegrating agents examples include corn starch, croscarmelose sodium, crospovidone (polyplasdone XL-10), sodium starch glycolate (EXPLOTAB® or PRIMOJEL®), or any combination of the foregoing.
  • the liquid dosage forms include syrups, solutions or suspensions.
  • the syrups, solutions or suspensions of the present invention typically contain pharmaceutically acceptable excipients such as a liquid carrier, e.g., water and/or alcohol, solvent, flavoring agents, stabilizing agents, coloring agents, viscosity increasing agents or mixtures thereof.
  • a liquid carrier e.g., water and/or alcohol
  • the pharmaceutically acceptable excipients employed in the syrups, solutions or suspensions of the present invention are described in Remington, the Science and Practice of Pharmacy, 21st Ed. (2006), pp. 745-775, published by Lippincott Williams & Wilkins ; United States Pharmacopeia 27 (2004), pp. 2809-2812 ; and Handbook of Pharmaceutical Excipients, 5th Ed. (2006), published by the Pharmaceutical Press and further described below.
  • Flavoring agents that may be used in the present invention include peppermint, spearmint, wintergreen, cinnamon, coconut, coffee, chocolate, vanilla, menthol, licorice, anise, apricot, caramel, pineapple, strawberry, raspberry, grape, cherry, mixed berry, tropical fruits, mint, and mixtures thereof.
  • Coloring agents that may be employed in the present invention include FD&C-type dyes and lakes, fruit and vegetable extracts, titanium dioxide, and mixtures thereof.
  • Viscosity increasing agents have been described previously, and a few representative examples that may be included in the liquid dosage forms include methylcellulose, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, acacia, agar, alginate, carrageenan, gum tragacanth, collagen, carboxypolymethylene, glyceryl monostearate, monostearate, polyvinylpyrrolidone, polyacrylamide, and mixtures thereof.
  • the composition of the present invention comprises a tablet, soft gelatin capsule or hard gelatin capsule for oral administration twice or three times a day wherein the tablet or capsule comprises a combination of THC and CBD along with a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier examples of methods for preparing the capsules and pharmaceutically acceptable excipients that may be used in the capsule can be found in U.S. Patent Nos. 6,703,418 and 8,741,341 .
  • the THC may be in the form of dronabinol, also known as delta-9-tetrahydrocannabinol and ⁇ 9-THC.
  • the THC and CBD should be present in the tablet or capsule in a ratio of about 1:1 to about 1:200, preferably a ratio of about 1:2 to about 1:190 and most preferably a ratio of about 1:3 to about 1:180.
  • the amount of THC in the tablet or capsule will be equal to the amount of CBD or the amount of CBD will exceed the amount of THC.
  • Some embodiments of the tablets and capsules will comprise THC and CBD in a weight ratio of THC to CBD ranging from a low value of 1:1; 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 or 1:10 to an upper value of 1:200, 1:175; 1:150; 1:125; 1:100; 1:75: 1:50, 1:25, 1:20 or any values in between the lower and upper ranges.
  • the weight ratio of THC to CBD in the tablet or capsule may range for example from 1:2 to 1:150, 1:4 to 1:175, 1:5 to 1:100, 1:5 to 1:50 and any values between the upper and lower ranges including but not limited to the values provided in the Example herein.
  • the tablets or capsules are substantially free (i.e., less than 1 wt% of the total cannabinoid content, less than 0.5 wt% of the total cannabinoid content, less than 0.1 wt% of the total cannabinoid content) or free of any cannabinoid other than THC and CBD and are substantially free or free of any terpene.
  • Each tablet or capsule will further comprise: (i) about 1-100 mg of THC, preferably 2-75 mg of THC and most preferably 5-50 mg of THC and (ii) about 1-1000 mg of CBD, preferably 2-850 mg of CBD and most preferably 5-700 mg of CBD.
  • the target of the oral administration of the tablet or capsule is to obtain a steady state plasma level of THC ranging from 0.25 ng/mL to 25 ng/mL, preferably 0.5 ng/mL to 17.5 ng/mL and most preferably 1 ng/mL to 12.5 ng/mL and a steady state plasma level of CBD greater than 0.5 ng/mL, preferably greater than 1 ng/mL and most preferably greater than 3 ng/mL.
  • the oral administration of the tablet or capsule may begin at a lower dose and increased over 3 to 14 days until the desired dosing level is obtained with a twice or thrice a day administration that will provide the target steady state plasma level.
  • the foregoing tablet or capsule comprising the combination of THC and CBD is particularly useful in treating the symptoms of myotonic dystrophy type 1 (DM1) and type 2 (DM2) and improving the overall quality of the patient's life by reducing pain, anxiety and improving muscle movement of the all affected muscles, including gastrointestinal muscles.
  • the foregoing tablet or capsule comprising the combination of THC and CBD should reduce the time for muscle relaxation following contraction as measured by any conventional method employed in the art including but not limited to grip relaxation time as described in Logigian et al., "Mexiletine is an Effective Antimyotonia Treatment in Myotonic Dystrophy Type 1," Neurology, (2010) 74(18), pp.1441-1448 .
  • the reduction in time for muscle relaxation can be measured by determining the time required for relaxation of the grip or contraction of a patient's hand to relax following a three second maximal voluntary isometric contraction.
  • a computer program measures the peak force during the three second contraction then measures the time to obtain various reductions in the peak force such as 90%, 75%, 50%, 25%, 5% and 0%.
  • the reduction times are compared to a baseline obtained prior to treatment and after treatment, preferably 1-4 hours after initial administration, after 7 days of administration and/or after obtaining steady state plasma levels of THC and CBD.
  • administration of the foregoing tablet or capsule comprising the combination of THC and CBD should reduce the pain and/or anxiety a patient experiences as determined by use of a visual analog scale that measures pain intensity and a visual analog scale that measures anxiety.
  • administration of the foregoing tablet or capsule comprising the combination of THC and CBD should improve muscle weakness and/or delay the muscle deterioration as measured by any known analytical method such as the MFM-32 or MFM-20, or 6 minute walking test, previously described.
  • the composition of the present invention comprises a solution or suspension for oral administration twice or three times a day wherein the solution or suspension comprises a combination of THC and CBD along with a pharmaceutically acceptable liquid carrier.
  • the solution or suspension comprises a combination of THC and CBD along with a pharmaceutically acceptable liquid carrier.
  • THC and CBD should be present in the solution or suspension in a ratio of about 1:1 to about 1:200, preferably a ratio of about 1:2 to about 1:190 and most preferably a ratio of about 1:3 to about 1:180.
  • the amount of THC in the solution or suspension will be equal to the amount of CBD or the amount of CBD will exceed the amount of THC.
  • Some embodiments of the solution or suspension comprising THC and CBD will contain a weight ratio of THC to CBD ranging from a low value of 1:1; 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 or 1:10 to an upper value of 1:200, 1:175; 1:150; 1:125; 1:100; 1:75: 1:50, 1:25, 1:20 or any values in between the lower and upper ranges.
  • the weight ratio of THC to CBD in the tablet or capsule may range from 1:3 to 1:100, 1:4 to 1:75, 1:5 to 1:50, and any values between the upper and lower ranges including but not limited to the values provided in the Example herein.
  • the solutions or suspension are substantially free (i.e. less than 1 wt% of the total cannabinoid content, less than 0.5 wt% of the total cannabinoid content, less than 0.1 wt% of the total cannabinoid content) or free of any cannabinoid other than THC and CBD and are substantially free or free of any terpene.
  • Each dose of the solution or suspension will further comprise: (i) about 0.1-50 mg/mL of THC, preferably 0.5-25 mg/mL of THC and most preferably 1-20 mg/mL of THC and (ii) about 5-100 mg/mL of CBD, preferably 7.5-80 mg/mL of CBD and most preferably 10-50 mg/mL of CBD.
  • the target of the oral administration of the solution or suspension is to obtain a steady state plasma level of THC ranging from 0.25 ng/mL to 25 ng/mL, preferably 0.5 ng/mL to 17.5 ng/mL and most preferably 1 ng/mL to 12.5 ng/mL and a steady state plasma level of CBD greater than 0.5 ng/mL, preferably greater than 1 ng/mL and most preferably greater than 3 ng/mL.
  • the oral administration of the solution or suspension may begin at a lower dose and increased over 3 to 14 days until the desired dosing level is obtained with a twice or thrice a day administration that will provide the target steady state plasma level.
  • the foregoing solutions or suspensions comprising the combination of THC and CBD is particularly useful in treating the symptoms of myotonic dystrophy type 1 (DM1) and type 2 (DM2) and improving the overall quality of the patient's life by reducing pain, anxiety and improving muscle movement of all affected muscles, including gastrointestinal muscles. More specifically, the foregoing solutions or suspensions comprising the combination of THC and CBD should reduce the time for muscle relaxation following contraction as measured by any conventional method employed in the art including but not limited to the previously described grip relaxation test. Similarly, administration of the foregoing solution or suspensions comprising the combination of THC and CBD should reduce the patient's pain and/or anxiety and should improve muscle weakness and/or delay the muscle deterioration as measured by any known analytical method such as previously described.
  • nasal compositions for the administration of a combination according to the invention.
  • the nasal compositions may be in the form of a liquid, preferably a solution of suspension that can be sprayed onto or applied to the nasal passages via drops or swabs.
  • the nasal compositions may contain inert diluents and/or solvents commonly used in the art. Water is the preferred solvent; however, combinations of water with other physiologically acceptable solvents are also contemplated.
  • solvents, solubilizing agents and emulsifiers suitable for use in place of, or in addition to, water include but are not limited to saturated aliphatic mono- and polyvalent alcohols which contain 2-6 carbon atoms (including, but not limited to, ethanol, 1,2-propylene glycol, sorbitol, and glycerine), polyglycols such as polyethylene glycols, and surfactants/emulsifiers like the fatty acid esters of sorbitan, and mixtures thereof.
  • Oils, in particular, cottonseed, peanut, or corn oils, may also be added to the compositions.
  • the combination of the additional solvents in the aqueous solution should preferably not exceed about 15% (w/v) of the total composition.
  • the nasal compositions of the present invention may further comprise one or more preservatives and/or one or more stabilizers.
  • Preservatives that are suitable for use in the compositions of the invention include, but are not limited to, edetic acid and their alkali salts such as disodium EDTA and calcium EDTA, benzyl alcohol, methylparaben, propylparaben, butylparaben, chlorobutanol, phenylethyl alcohol, benzalkonium chloride, thimerosal, propylene glycol, sorbic acid, and benzoic acid derivatives.
  • the preservatives should be used at a concentration of from about 0.001% to about 0.5% (w/v) in the final composition.
  • benzalkonium chloride used at a concentration of from about 0.001% to about 0.5%, preferably from about 0.005% to about 0.1% (w/v)
  • edetic acid used at a concentration of from about 0.005% to about 0.1% (w/v)
  • edetic acid used at a concentration of from about 0.005% to about 0.1% (w/v)
  • the nasal compositions of the present invention may further comprise one or more buffering agents that are used to adjust and/or maintain the compositions in the desired pH range.
  • buffering agents that are suitable for use in the compositions of the invention include, but are not limited to, citric acid, sodium citrate, sodium phosphate (dibasic, heptahydrate form), and boric acid or equivalent conventional buffers, and combinations thereof.
  • the appropriate amounts of buffers and buffering agents, or combinations thereof, that are to be used in the compositions of the invention are described in the United States Pharmacopoeia, Remington: The Science and Practice of Pharmacy , and the like.
  • nasal compositions of the invention may also further comprise one or more taste-masking agents, one or more flavoring agents, one or more sweetening agents, and/or a combination of such agents.
  • the nasal compositions may further comprise one or more water-soluble viscosity-increasing agents.
  • Such agents are preferably used at the concentration of about 0.01% to about 5.0% (w/v), in order to typically produce a viscosity of the final solution between about 2 and about 300 centipoise.
  • Viscosity-increasing agents that are suitable for use in accordance with the present invention include, but are not limited to, polyvinylpyrrolidones, cellulose derivatives including, but not limited to, hydroxyethyl cellulose, carboxymethyl cellulose or its salts, hypromellose, carrageenan, guar gum, alginates, carbomers, polyethylene glycols, polyvinyl alcohol, and xanthan gum.
  • One embodiment of the invention is directed to inhalation compositions for the administration of a combination according to the invention to the respiratory system of the patient.
  • the composition may be in the form of a powder, aerosol or vapor, which is inhaled by the patient to deliver the CBD and THC to the respiratory system of the patient, preferably the lungs.
  • the powders, solutions and suspensions that comprise the combination according to the invention for delivery to the respiratory system of the patient may be prepared by any means commonly employed in the art, and employ excipients as described above for preparation of the solid and liquid oral dosage forms.
  • the inhalation compositions may be delivered to a patient's respiratory system, using apparatuses commonly known in the art such as those described in U.S. Patent Nos. 5,349,945 ; 5,394,868 ; 5,674,472 ; 5,766,573 ; 5,860,419 ; 6,641,800 ; 6,521,212 ; 9,339,507 and U.S. Patent Publication No. 2004/0265238 .
  • CBD/THC cannabidiol and tetrahydrocannabinol
  • the overall treatment lasted 4 weeks.
  • the following assessments were performed weekly to monitor treatment response: myotonia behaviour scale (MBS), hand opening time, fatigue severity scale (FSS, maximal score 63) and Epworth sleepiness scale (ESS, maximal score 24).
  • the MBS is a patient-reported outcome validated in patients with non-dystrophic myotonia to assess the impact of myotonia in daily duties and activities. It consists of six statements and participants have to choose the one best describing their condition ranging from 0 (no stiffness) to 5 point (incapacitating stiffness).
  • the hand opening time was assessed by video-documented timing hand opening with a stopwatch after tight hand closure for 5 seconds. Five consecutive trials were performed. Manual muscle testing was performed at baseline and at end of the 4 th week of treatment.
  • MRC Medical Research Council scale
  • CBD/THC side effects were mostly mild and did not cause any patient to withdraw therapy. The most common side effect was constipation, which was particularly evident at higher doses of CBD/THC. A detailed summary of patients' reported side effects is represented in Table 2. Table. 2. CBD/THC side effects in six myotonic patients Side effects N of patients Severity Constipation 4/6 moderate Bloating 2/6 mild Sedation 1/6 mild Depression/Anxiety 1/6 mild Dizziness/drowsiness 0/6 - Dry mouth 0/6 - Reflux 0/6 - Diarrhoea 0/6 - Nausea/vomiting 0/6 - Weight gain 0/6 - Other 0/6 -
  • DM2 This 65 years-old woman was diagnosed with DM2 at the age of 54 years. As DM2-related comorbidities she has diabetes mellitus type 2 without diabetic neuropathy, and controlled paroxysmal atrial fibrillation. Her main muscular complaints have always been a severe grip myotonia and myotonia of the legs while walking, as well as persistent myalgia especially at lower back. In the last several years she developed a proximal and axial muscle weakness (MRC grade 4). Several drugs have been tried in the past to improve her myotonia e.g. mexiletine, carbamazepine, pregabalin and were suspended due to inefficacy and risk of cardiac arrhythmias.
  • cannabinoids refer to any drug able to act on the endocannabinoid system, which is widely expressed in the central and peripheral nervous system.
  • Cannabinoids mainly exert their effects by binding to two G-coupled protein receptors (GCPRs): CB1 and CB2; however other receptors (GPR55, GPR119, TRPV1, etc.) are also known to be involved.
  • CB1 are expressed in nearly all tissues but especially in the presynaptic neurons of CNS, dorsal root ganglia and spinal cord.
  • CB2 receptors are mainly present on immune cells and in small amounts also in the CNS.
  • the plant Cannabis Sativa contains more than 100 different cannabinoids and among those the best studied and used for their medical properties are cannabidiol (CBD) and tetrahydrocannabinol (THC).
  • CBD cannabidiol
  • THC tetrahydrocannabinol
  • CBD has a lower binding affinity for CB receptors; it is usually safe, well tolerated and able to counteract the psychoactive effects of THC antagonizing CB1 receptors by allosteric or indirect mechanisms. CBD also exerts an anti-inflammatory and analgesic effect as an inverse agonist of CB2 receptors and a TRPV1 agonist. The balance of THC and CBD is then responsible for the safety and therapeutic effect of cannabis based products.
  • CBD and THC have proven empirical efficacy in different conditions (spasticity in multiple sclerosis, treatment resistant epilepsies, nausea and vomiting due to chemotherapy, chronic pain, reduced appetite and weight loss associated with HIV/AIDS, and many other diseases as off label therapy).
  • great heterogeneity is found in the literature as regards types of cannabis based products, pharmacokinetics, CBD/THC composition, so that establishing the optimal dosing strategy is difficult.
  • Nabiximols is a cannabinoid drug licenced also in Germany for the treatment of multiple sclerosis with a 1:1 ratio of CBD/THC.
  • a nabiximols composition was adopted for patients to a lower concentration of THC, to a 10:1 (low ratio dose) and 6:1 (high ratio dose) ratios of CBD/THC. All six treated patients experienced various degrees of improvement of myotonia, especially if assessed by the myotonia behaviour scale. These changes in MBS correlated with higher doses of CBD/THC. Objective improvements of myotonia were also detected by measuring the hand opening time, already in the first 2 weeks of treatment, thus mostly anticipating changes in MBS. The higher ratio of CBD/THC did not produce further improvements of hand-opening time.
  • Muscle relaxation and reduced spasticity are well-documented effects of cannabis-based products; it is however believed that these effects are mainly due to central nervous mechanisms.
  • Novel insights on the peripheral effects of cannabinoids in skeletal muscles are provided by Olah et al. and might partially explain the reduction of myotonia, muscle stiffness and myalgias observed in our patients.
  • CB1 knockout animal model were used to show that cannabinoids interfere with intramuscular Ca 2+ homeostasis and excitation-contraction coupling (ECC).
  • Muscular CB1 receptors are localized on the I-bands around the Z-lines of adult muscle fibres and their activation through a selective agonist inhibited the ryanodine receptor-mediated sarcoplasmic release of Ca 2+ and reduced the Ca 2+ sensitivity of contractile proteins thus reducing muscle contraction.
  • CB1 also CB2 and TRPV1 receptors are known to be expressed in human skeletal muscle; however, most of their functions is largely unknown.
  • Preliminary data have shown an involvement in regulating muscular glucose uptake, energy metabolism and formation of muscle fibres.
  • the injection of CBD in dystrophic mdx mice promoted myotube formation and reduced inflammation mostly via activation of TRPV1 and TRPA1. The potential implication of these aspects in myotonia and myalgia still needs to be investigated.
  • DM2 patients with quantitative sensory testing (QST) and transcriptome analysis on muscle biopsies found that DM2 patients had altered pain pressure thresholds, mechanical pain sensation and wind-up ratios in comparison to controls, thus suggesting the presence of peripheral sensitization mechanisms known to be a trigger for central sensitization.
  • the endocannabinoid system plays a central role in the inhibition of nociceptive transmission acting at supraspinal (thalamus, limbic system, periaqueductal gray) spinal and peripheral levels. This peripheral nociceptive modulation is believed to be mainly due to CB2, TRPV1 receptors and other indirect mechanisms also involving the opioid system.
  • Cannabidiol as used in patients is known to have a CB2- and TRPV1-mediated anti-inflammatory and analgesic function and to upregulate ⁇ - and ⁇ -opioid receptors with a mechanism mediated by serotonin receptor (5-HT1A).
  • the only assessment method for myalgia has been pain-VAS making it difficult to assess whether the improvement experienced is mainly due to peripheral or central mechanisms.
  • the DM2 patient gained strength and was again able to perform repetitive squats for the first time in 4 years.
  • CBD/THC medicinal bowel syndrome

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP19179559.0A 2019-06-11 2019-06-11 Zusammensetzungen zur behandlung von dystrophien und myotonie Pending EP3750528A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19179559.0A EP3750528A1 (de) 2019-06-11 2019-06-11 Zusammensetzungen zur behandlung von dystrophien und myotonie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19179559.0A EP3750528A1 (de) 2019-06-11 2019-06-11 Zusammensetzungen zur behandlung von dystrophien und myotonie

Publications (1)

Publication Number Publication Date
EP3750528A1 true EP3750528A1 (de) 2020-12-16

Family

ID=66826848

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19179559.0A Pending EP3750528A1 (de) 2019-06-11 2019-06-11 Zusammensetzungen zur behandlung von dystrophien und myotonie

Country Status (1)

Country Link
EP (1) EP3750528A1 (de)

Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3560528A (en) 1967-05-19 1971-02-02 Theodor Petrzilka 6a,10a-trans-6a,7,10,10a-tetrahydrodibenzo (b,d)-pyran production
US3668224A (en) 1970-07-02 1972-06-06 Theodor Petrzilka PROCESS OF PRODUCING 6a, 10a-TRANS-6a,7,8,10a-TETRAHYDRODIBENZO (b,d)-PYRANS
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4855294A (en) 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
US4915949A (en) 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US5349945A (en) 1990-11-26 1994-09-27 Minnesota Mining And Manufacturing Company Aerosol dispenser comprising an indicator assembly
US5394868A (en) 1992-06-25 1995-03-07 Schering Corporation Inhalation device for powdered medicaments
US5429816A (en) 1992-05-12 1995-07-04 Procter & Gamble Antiperspirant gel stick compositions
US5552136A (en) 1994-05-25 1996-09-03 The Procter & Gamble Company Gel stick compositions comprising optically enriched gellants
US5643588A (en) 1994-11-28 1997-07-01 The Procter & Gamble Company Diaper having a lotioned topsheet
US5674472A (en) 1991-12-12 1997-10-07 Glaxo Group Limited Canisters containing aerosol formulations containing P134a and fluticasone propionate
US5766573A (en) 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5860419A (en) 1990-03-02 1999-01-19 Glaxo Group Limited Inhalation device
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6641800B1 (en) 1991-09-25 2003-11-04 Fisons Ltd. Pressurized aerosol compositions comprising powdered medicament dispersed in hydrofluoroalkane
US6703418B2 (en) 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US6946120B2 (en) 1998-04-22 2005-09-20 Connetics Australia Pty. Ltd. Pharmaceutical composition
US7186850B2 (en) 2001-05-25 2007-03-06 Johnson Matthey Public Limited Company Synthesis of cannabinoids
US20070269379A1 (en) 2003-07-23 2007-11-22 Samir Mitragotri Penetration Enhancer Combinations for Transdermal Delivery
US7344736B2 (en) 2002-08-14 2008-03-18 Gw Pharma Limited Extraction of pharmaceutically active components from plant materials
US7449613B2 (en) 2001-07-03 2008-11-11 The Procter & Gamble Company Film-forming compositions for protecting skin from body fluids and articles made therefrom
US7524881B2 (en) 2002-02-01 2009-04-28 Resolution Chemicals Limited Production of Δ 9 tetrahydrocannabinol
US7674922B2 (en) 2005-09-29 2010-03-09 Albany Molecular Research, Inc. Process for production of delta-9-tetrahydrocannabinol
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
US8324408B2 (en) 2005-06-22 2012-12-04 Bionorica Ag Method for the preparation of dronabinol
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
US8741341B2 (en) 2012-05-07 2014-06-03 Insys Therapeutics, Inc. Manufacturing and packaging room temperature stable dronabinol capsules
US8895078B2 (en) 2000-10-17 2014-11-25 Bionorica Ethics Gmbh Method for producing an extract from cannabis plant matter, containing a tetrahydrocannabinol and a cannabidiol and cannabis extracts
US9034395B2 (en) 2001-05-04 2015-05-19 Gw Pharma Limited Processes and apparatus for extraction of active substances and enriched extracts from natural products
US9339507B2 (en) 2006-05-15 2016-05-17 United Therapeutics Corporation Treprostinil administration by inhalation
US9345771B2 (en) 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
WO2018102029A1 (en) * 2016-12-02 2018-06-07 Receptor Life Sciences Fast-acting plant-based medicinal compounds and nutritional supplements
WO2018175992A1 (en) * 2017-03-23 2018-09-27 Receptor Life Sciences Rapid and controlled delivery of compositions with restored entourage effects

Patent Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3560528A (en) 1967-05-19 1971-02-02 Theodor Petrzilka 6a,10a-trans-6a,7,10,10a-tetrahydrodibenzo (b,d)-pyran production
US3668224A (en) 1970-07-02 1972-06-06 Theodor Petrzilka PROCESS OF PRODUCING 6a, 10a-TRANS-6a,7,8,10a-TETRAHYDRODIBENZO (b,d)-PYRANS
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4915949A (en) 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4855294A (en) 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
US5766573A (en) 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5860419A (en) 1990-03-02 1999-01-19 Glaxo Group Limited Inhalation device
US5349945A (en) 1990-11-26 1994-09-27 Minnesota Mining And Manufacturing Company Aerosol dispenser comprising an indicator assembly
US6703418B2 (en) 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
US6641800B1 (en) 1991-09-25 2003-11-04 Fisons Ltd. Pressurized aerosol compositions comprising powdered medicament dispersed in hydrofluoroalkane
US5674472A (en) 1991-12-12 1997-10-07 Glaxo Group Limited Canisters containing aerosol formulations containing P134a and fluticasone propionate
US5429816A (en) 1992-05-12 1995-07-04 Procter & Gamble Antiperspirant gel stick compositions
US5394868A (en) 1992-06-25 1995-03-07 Schering Corporation Inhalation device for powdered medicaments
US5552136A (en) 1994-05-25 1996-09-03 The Procter & Gamble Company Gel stick compositions comprising optically enriched gellants
US5643588A (en) 1994-11-28 1997-07-01 The Procter & Gamble Company Diaper having a lotioned topsheet
US6946120B2 (en) 1998-04-22 2005-09-20 Connetics Australia Pty. Ltd. Pharmaceutical composition
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US8895078B2 (en) 2000-10-17 2014-11-25 Bionorica Ethics Gmbh Method for producing an extract from cannabis plant matter, containing a tetrahydrocannabinol and a cannabidiol and cannabis extracts
US9034395B2 (en) 2001-05-04 2015-05-19 Gw Pharma Limited Processes and apparatus for extraction of active substances and enriched extracts from natural products
US7186850B2 (en) 2001-05-25 2007-03-06 Johnson Matthey Public Limited Company Synthesis of cannabinoids
US7449613B2 (en) 2001-07-03 2008-11-11 The Procter & Gamble Company Film-forming compositions for protecting skin from body fluids and articles made therefrom
US7524881B2 (en) 2002-02-01 2009-04-28 Resolution Chemicals Limited Production of Δ 9 tetrahydrocannabinol
US7344736B2 (en) 2002-08-14 2008-03-18 Gw Pharma Limited Extraction of pharmaceutically active components from plant materials
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US20070269379A1 (en) 2003-07-23 2007-11-22 Samir Mitragotri Penetration Enhancer Combinations for Transdermal Delivery
US8324408B2 (en) 2005-06-22 2012-12-04 Bionorica Ag Method for the preparation of dronabinol
US7674922B2 (en) 2005-09-29 2010-03-09 Albany Molecular Research, Inc. Process for production of delta-9-tetrahydrocannabinol
US9339507B2 (en) 2006-05-15 2016-05-17 United Therapeutics Corporation Treprostinil administration by inhalation
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
US8741341B2 (en) 2012-05-07 2014-06-03 Insys Therapeutics, Inc. Manufacturing and packaging room temperature stable dronabinol capsules
US9345771B2 (en) 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
WO2018102029A1 (en) * 2016-12-02 2018-06-07 Receptor Life Sciences Fast-acting plant-based medicinal compounds and nutritional supplements
WO2018175992A1 (en) * 2017-03-23 2018-09-27 Receptor Life Sciences Rapid and controlled delivery of compositions with restored entourage effects

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy", UNITED STATES PHARMACOPOEIA
"United States Pharmacopeia", vol. 27, 2004, pages: 2809 - 2812
AMIN HAGHIGHAT JAHROMI: "The doctoral dissertation", 2013, UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN, article "Advances in Myotonic Dystrophy Type 1 Drug Discovery Through Design of Novel Ligands and Mechanism Establishment"
BERARD ET AL.: "A Motor Function Measure Scale for Neuromuscular Diseases. Construction and Validation Study", NEUROMUSCULAR DISORDERS, vol. 15, 2005, pages 463 - 470
FEDERICA MONTAGNESE ET AL: "A role for cannabinoids in the treatment of myotonia? Report of compassionate use in a small cohort of patients", JOURNAL OF NEUROLOGY - ZEITSCHRIFT FUER NEUROLOGIE, 26 October 2019 (2019-10-26), DE, XP055650376, ISSN: 0340-5354, DOI: 10.1007/s00415-019-09593-6 *
FOFF ET AL.: "Therapeutic Development in Myotonic Dystrophy Type I", MUSCLE NERVE, vol. 44, no. 2, 2011, pages 160 - 169
LOGIGIAN ET AL.: "Mexiletine is an Effective Antimyotonia Treatment in Myotonic Dystrophy Type 1", NEUROLOGY, vol. 74, no. 18, 2010, pages 1441 - 1448, XP055520786, DOI: doi:10.1212/WNL.0b013e3181dc1a3a
SCOTTROFF: "Remington, the Science and Practice of Pharmacy", 2006, LIPPINCOTT WILLIAMS & WILKINS, pages: 1058 - 1092

Similar Documents

Publication Publication Date Title
US11084788B2 (en) Formulation for soft anticholinergic analogs
US10702495B2 (en) Method and compositions for treating dystrophies and myotonia
US10952990B2 (en) Formulation for soft anticholinergic analogs
HU199678B (en) Process for producing aerosols containing nitroglicerol
AU2023202689B2 (en) Formulation for soft anticholinergic analogs
US20210267998A1 (en) Methods and compositions for treatment of peripheral neuropathies
WO2018236957A1 (en) METHOD AND COMPOSITIONS FOR TREATING REST-FREE LEG SYNDROME
EP3750528A1 (de) Zusammensetzungen zur behandlung von dystrophien und myotonie
US11260063B2 (en) Method and compositions for treating psoriasis
EP3692981B1 (de) Topische zusammensetzung zur verwendung bei der behandlung von psoriasis
CN110709054B (zh) 水包油乳液

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KLUMPERS, LINDA

Inventor name: SCHOSER, BENEDIKT

Inventor name: GOLDFARB, ROBERT

Inventor name: FRIEDLAND, JEFFREY

17P Request for examination filed

Effective date: 20210616

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220819

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240719